Candesartan vs Pembrolizumab

Candesartan vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Candesartan and Pembrolizumab.

Mechanism of Action

Candesartan: Prodrug hydrolyzed to active form; selective angiotensin II type 1 receptor blocker.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Candesartan — 9 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Candesartan — C33H34N6O6.

Molecular Weight: Candesartan — 610.6640 g/mol.

Type: Candesartan — Small molecule; Pembrolizumab — Antibody.